ArticleJACC. Case reports2026
Transcatheter Tricuspid Valve Edge-to-Edge Repair in a Patient Following Heart Transplantation.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ventricular Volumetric Changes After Transcatheter Tricuspid Valve Replacement in a Heart Transplant Recipient.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter tricuspid valve edge-to-edge repair (T-TEER) is an emerging therapy for severe tricuspid regurgitation (TR), but experience in heart transplant recipients is limited. CASE SUMMARY: A 42-year-old man, 1-year post heart transplantation, presented with severe volume overload and dyspnea. Echocardiography confirmed severe TR with a flail posterior leaflet. Given high surgical risk, he underwent T-TEER with TriClip (Abbott), reducing TR to moderate with resolution of hepatic vein systolic flow reversal. Later, recurrent hypervolemia from missed dialysis led to TR progression. After kidney transplantation, imaging demonstrated stable clip positioning with moderate residual TR. DISCUSSION: Severe TR affects nearly 20% of heart transplant recipients and predicts mortality and retransplantation. Early TR results from biopsy-related valve trauma, whereas late TR links to graft dysfunction and rejection. Surgical management carries high morbidity and failure rates. Percutaneous options like T-TEER are promising but require further validation. TAKE-HOME MESSAGE: T-TEER is feasible in heart transplant recipients and may bridge to eligibility for other lifesaving therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.